Everything below concerns aggregation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
| Property | Value | Notes |
|---|---|---|
| Storage temperature | -20 °C or below | Lyophilized powder; -80 °C for long-term archival |
| Post-reconstitution storage | 2-8 °C | Refrigerated; avoid repeated freeze-thaw |
| Routine purity method | Reversed-phase HPLC | Separates peptide from related impurities |
| Identity confirmation | Mass spectrometry | Confirms molecular mass and detects truncation |
| Water solubility | Freely soluble | Depends on salt form and buffer composition |
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
=== Discontinued === Acebilustat (CTX-4430; EP-501) – leukotriene A4 (LTA4H) hydrolase inhibitor Afamelanotide (CUV-1647; EPT-1647; Melanotan I; Melanotan; Prenumbra; Scenesse) – melanocortin receptor agonist BBI-3000 – retinoid X receptor agonist BMX-010 (MnTE-2-PyP) – reactive oxygen species (ROS) scavenger and radioprotector Botulinum toxin A liquid (AI-09) – acetylcholine release inhibitor and neuromuscular blocking agent Botulinum toxin A topical (ANT-1207) – acetylcholine release inhibitor and neuromuscular blocking agent Cioteronel (CPC-10997; Cyoctol; X-Andron) – antiandrogen (androgen receptor antagonist) Diroleuton (DGLA; DHLA; DS-107; RO-12-1989) – omega-6 fatty acid and anti-inflammatory DMVT-503 (RVT-503) – undefined mechanism of action DX-0385 – retinoic acid metabolism modulator Encapsulated tretinoin cream – retinoid (retinoic acid receptor agonist) Epristeride (Aipuliete; ONO-9302; SKF-105657) – 5α-reductase inhibitor Falecalcitriol (DSC-103; F6VD3; flocalcitriol; Fulstan; hexafluorocalcitriol; hexafluorovitamin D3; Hornel; SM-8000; ST-630) – vitamin D/calcitriol analogue Gevokizumab (S-78989; VPM-087; XMA-005.2) – monoclonal antibody against interleukin-1β Hypochlorous acid (PR-013; PR-022) – disinfectant and other actions Imsidolimab (ANB-019) – monoclonal antibody against the interleukin-36 receptor Incyclinide (chemically modified tetracycline 3; CMT-3; COL-3; Metastat) – chemically modified tetracycline and matrix metalloproteinase inhibitor (no antibiotic activity) Ingenol disoxate (LEO-43204) – undefined mechanism of action JNJ-10229570 – melanocortin MC5 receptor antagonist MDI-301 – undefined mechanism of action MK-434 (MK-0434) – 5α-reductase inhibitor MTCH-24 (Zilex; Zorex) – undefined mechanism of action PF-06423264 – acetyl-CoA carboxylase inhibitor PSK-3841 (HMR-3841; RU-58841) – antiandrogen (androgen receptor antagonist) Research programme: acne therapeutics - Praxis – undefined mechanism of action Research programme: tetracycline derivatives - Paratek Pharmaceuticals (P-004292) – tetracycline derivatives Rose bengal sodium (PH-10; Provecta; PV-10; rose bengal; Xantryl) – immunomodulator and other actions Santalum album ointment (albuterpenoid; East Indian sandalwood oil) – undefined mechanism of action Talarozole (R115866; Rambazole) – retinoic acid metabolism modulator Thykamine (PCT-233; PUR-0110) – undefined mechanism of action (anti-inflammatory) Valproic acid topical (Avugane; Baceca; G2M-777) – histone deacetylase inhibitor and other actions XEN-801 (XEN801) – stearoyl-CoA desaturase inhibitor XOMA-629 (XMP-629) – endotoxin inhibitor Zileuton (A-64077; Abbott-64077; ABT-077; CRTX-073; CTI-02; Zyflo) – 5-lipoxygenase inhibitor
=== Singles series and Full Cold Moon (2012–present) === In September 2012, Eisold announced Cold Cave would be touring the US later in the year, he would be recording a new album, and that the new live lineup included: Hunter Burgan (AFI), London May (Samhain), Jessie Nelson, and Cody Votolato (The Blood Brothers). This lineup was exclusive to this two-and-a-half-week tour and Eisold said performing with a full band was something that failed to materialize during Cherish the Light Years tours. While continuing to work on a follow-up to Cherish the Light Years and not under contract with a label, Eisold began independently releasing a series of stand-alone singles. Eisold wrote and recorded these new songs by himself similar to how songs on Cremations and Love Comes Close were crafted. He said they were created "by myself, at a desk in my apartment. It was freeing and exciting in a way because I didn't owe anyone an album. I got to just make them to make them. The songs were minimal, honest, electronic and without help." The first single in the series was "A Little Death to Laugh." The single was released in October 2012 through Heartworm and a music video for the song was released in March 2013. In 2013, Eisold released "Oceans with No End" (through Jacob Bannon's Deathwish Inc.), "God Made the World" and "Black Boots", for which Slava Tsukerman, known for his 1982 film Liquid Sky, directed a music video. In October 2013, Cold Cave released a digital-only, fifth stand-alone single titled "Nausea, The Earth and Me."
Cloning of the YAP1 gene facilitated the identification of a modular protein domain, known as the WW domain. Two splice isoforms of the YAP1 gene product were initially identified, named YAP1-1 and YAP1-2, which differed by the presence of an extra 38 amino acids that encoded the WW domain. Apart from the WW domain, the modular structure of YAP1 contains a proline-rich region at the very amino terminus, which is followed by a TID (TEAD transcription factor interacting domain). Next, following a single WW domain, which is present in the YAP1-1 isoform, and two WW domains, which are present in the YAP1-2 isoform, there is the SH3-BM (Src Homology 3 binding motif). Following the SH3-BM is a TAD (transactivation domain) and a PDZ domain-binding motif (PDZ-BM) (Figure 1).
=== Interest in William James === During his first trip to the United States with Freud, Jung was introduced to the elder philosopher and psychologist William James, known as the "Father of American psychology," whose ideas Jung would incorporate into his own work. Jung connected with James around their mutual interests in mysticism, spiritualism and psychical phenomena. James wrote to a friend after the conference stating Jung "left a favorable impression," while "his views of Freud were mixed." James died about eleven months later. The ideas of both Jung and James, on topics including hopelessness, self-surrender, and spiritual experiences, were influential in the development and founding of the international altruistic, spiritual movement Alcoholics Anonymous on 10 June 1935, in Akron, Ohio, a quarter of a century after James' death and in Jung's sixtieth year.
=== FDA approval === In 1988, twenty-six years after the 1962 introduction of breast implants filled with silicone gel, the U.S. Food and Drug Administration (FDA) investigated breast implant failures and the subsequent complications, and re-classified breast implant devices as Class III medical devices, and required from manufacturers the documentary data substantiating the safety and efficacy of their breast implant devices. In 1992, the FDA placed silicone-gel breast implants in moratorium in the U.S., because there was "inadequate information to demonstrate that breast implants were safe and effective". Nonetheless, medical access to silicone-gel breast implant devices continued for clinical studies of post-mastectomy breast reconstruction, the correction of congenital deformities, and the replacement of ruptured silicone-gel implants. The FDA required from the manufacturers the clinical trial data, and permitted their providing breast implants to the breast augmentation patients for the statistical studies required by the U.S. Food and Drug Administration. In mid-1992, the FDA approved an adjunct study protocol for silicone-gel filled implants for breast reconstruction patients, and for revision-surgery patients.
Sources: en.wikipedia.org
== Contraindications == Gepirone is contraindicated in people that have experienced an allergic reaction to gepirone, a corrected QT interval > 450 msec, a history of congenital long QT syndrome, use medications that strongly inhibit CYP3A4 (an enzyme involved in gepirone's metabolism), severe liver problems, or have used a monoamine oxidase inhibitor (MAOI) medication within 14 days.
== Recognition == In 2015, Yang was the winner of the Moran Medal of the Australian Academy of Science for her "significant contributions to the development of statistical methodology for analyzing molecular data arising in contemporary biomedical research". She was elected a Fellow of the Royal Society of New South Wales in 2025.
== Therapeutics targeting nonsense mutation diseases == Therapeutics for diseases caused by nonsense mutations attempt to recapitulate wild-type function by decreasing the efficacy of NMD, facilitating readthrough of the premature stop codon during translation, or editing the genomic nonsense mutation. Antisense oligonucleotides to suppress the expression of NMD and translation termination proteins are being explored in animal models of nonsense mutation-induced disease. Other RNA therapeutics under investigation include synthetic suppressor tRNAs that enable ribosomes to insert an amino acid, instead of initiating chain termination, upon encountering premature stop codons. CRISPR-Cas9 based single nucleotide substitutions have been used to generate amino acid codons from stop codons, achieving an editing success rate of 10% in cell cultures. Read-through has been achieved using small molecule drugs such as aminoglycosides and negamycin. An oxadiazole, ataluren (previously PTC124), facilitates the selective read-through of aberrant stop codons, rendering it a potential therapeutic against nonsense mutation-induced disease. Ataluren, sold under the tradename Translarna, is currently an approved treatment for Duchenne muscular dystrophy in the European Economic area and Brazil. However, phase III trials of Ataluren as a cystic fibrosis therapeutic have failed to meet their primary endpoints.
== Works cited == "The Best of 2004; The 14th Annual Computer Games Awards". Computer Games Magazine. No. 172. Fort Lauderdale, Florida: theGlobe.com. March 2005. pp. 48–56. "2004 Games of the Year". Computer Gaming World. No. 249. Cambridge, Massachusetts: Ziff Davis. March 2005. pp. 56–67. Retrieved November 3, 2020. Osborn, Chuck (2003). "Cover Story: Bloodlines - The Half Life 2 Engine Gets Dead Sexy". PC Gamer US. Vol. 10, no. 114. United States: Ace St. Germain. pp. 46–54. ISSN 1080-4471. Osborn, Chuck (2005). "Reviews - Vampire: The Masquerade - Bloodlines". PC Gamer US. Vol. 12, no. 132. United States: Ace St. Germain. pp. 92–94. ISSN 1080-4471.
Sources: en.wikipedia.org
The significant leaks of testimonies in the case are raising legal concerns for the Belgian authorities as they continue their investigation. Kaili's actions had already attracted suspicion among the members of her S&D party before her arrest. Dutch lawmaker Lara Wolters, who served in the European Parliament with the same political group as Kaili, described Kaili's modus operandi in an interview with the EU Scream podcast. According to Wolters, Kaili tried to prevent her from expressing views critical of Qatar during discussions in the European Parliament. Kaili's last known action in favour of Qatar before her arrest was casting a vote in the Civil Liberties Committee (of which she was not a member) in support of a report advocating for visa-free travel to the EU for Qatari citizens. While this vote was allowed under the European Parliament' rules, Kaili should have notified members and parliament staff of her intention to vote in advance, which she failed to do. German member Gabriele Bischoff said that Kaili's vote violated "internal rules".
== External links == The Effects of Nuclear Weapons Annotated bibliography for nuclear fission from the Alsos Digital Library The Discovery of Nuclear Fission Archived 2010-02-16 at the Wayback Machine Historical account complete with audio and teacher's guides from the American Institute of Physics History Center atomicarchive.com Nuclear Fission Explained Nuclear Files.org Archived 2018-03-08 at the Wayback Machine What is Nuclear Fission? Nuclear Fission Animation
=== Release === The first trailer was released on 9 February 2024 featuring to Deepa Balu as Reena, a medical intern on her first day at work. It was announced on 11 February that the series would be released in Tamil and dubbed into other Indian languages. It was also given a release date of 8 March 2024, coinciding with International Women's Day.
Sources: en.wikipedia.org
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.
It usually represents the proportion of total chromatographic area attributable to the main peak. That figure does not account for impurities that do not absorb at the detection wavelength or that co-elute with the main peak. It is a useful but incomplete indicator of overall quality.
Yes. Immunoassays and chromatographic methods recognize different molecular features and can yield divergent results. Even within one technique, differences in columns, gradients, and reference standards shift reported values. Comparable numbers require a shared procedure and a common standard.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.